Screening cancer patients for microsatellite instability (MSI) can provide pathologists, oncologists, and patients with information that characterizes tumors to help guide care and make more informed decisions.  With the growing demand for MSI testing and recognition of its value as a biomarker, the need for a reliable and cost-effective MSI test has increased in recent years. In this presentation, Ms. Oostdik will discuss the new OncoMate™ MSI Dx Analysis System, a FDA-cleared PCR-based MSI kit. The system uses the most sensitive panel of markers for MSI status detection, as included in multiple clinical guidelines. Topics in this presentation will include assay design, intended use, and clinical performance of OncoMate™ MSI Dx. The automated analysis software included in the system will also be discussed.

Learning objectives

• Present the relationship between mismatch repair deficiency and microsatellite instability
• Describe microsatellite instability detection using PCR followed by capillary electrophoresis (CE) analysis
• Describe the use of microsatellite instability status for Lynch Syndrome screening in colorectal cancer (CRC)
• Summarize the performance of the OncoMate™ MSI Dx Analysis System as an aid to identify colorectal cancer (CRC) patients who may benefit from further testing to screen for Lynch syndrome, the most common form of hereditary CRC